Trial Profile
An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Conbercept
- Indications Wet age-related macular degeneration
- Focus Pharmacodynamics
- Acronyms RELIANCE
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 01 Aug 2016 Status changed from recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.